Cutler Group’s Fennec Pharmaceuticals FENC Stock Holding History

Cutler Group’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,300	Closed	-$1K	–	4629
2022 Q3	$1K	Buy	+1,300	New	+$8.92K	﹤0.01%	4518

Other funds holding FENC

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Cutler Group's FENC Position: Q4 2022 in Review

Cutler Group sold out of Fennec Pharmaceuticals (FENC) in Q4 2022, closing a stake of 139 shares — an estimated $1K sold.

Cutler Group first reported a position in FENC in Q2 2020 and held it in 6 quarters. The position peaked at $6K in Q2 2020. 43 funds tracked by Wall St. Rank hold FENC as of Q4 2022.

Cutler Group reported no remaining Fennec Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 139 Fennec Pharmaceuticals shares in Q4 2022, an estimated $1K.
Cutler Group first reported a position in Fennec Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Cutler Group's Fennec Pharmaceuticals position peaked at $6K in Q2 2020.
43 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.